id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2016-E-2529-0008,FDA,FDA-2016-E-2529,"Determination of Regulatory Review Period for Purposes of Patent Extension; BRIVIACT ORAL SOLUTION, New Drug Application 205838",Notice,Determinations,2019-12-12T05:00:00Z,2019,12,2019-12-12T05:00:00Z,2020-02-11T04:59:59Z,2019-12-12T14:38:30Z,2019-26814,0,0,0900006484206b7a
FDA-2016-E-2529-0007,FDA,FDA-2016-E-2529,Letter to U.S. Patent and Trademark Office from FDA CDER,Other,Letter(s),2019-11-01T04:00:00Z,2019,11,2019-11-01T04:00:00Z,,2019-11-01T17:15:39Z,,0,0,0900006484115a24